Semaglutida e Tirzepatida: fiscalização, hype e futuro da farmácia I ABCAST 145

🚨 The market for semaglutide and tirzepatide has EXPLODED. But along with the hype… came inspections, technical notes, and new health alerts. In this episode of ABcast, I bring an in-depth analysis of: ⚠️ the absurd growth of GLP-1 agonists ⚠️ the impact of semaglutide and tirzepatide on compounding pharmacies ⚠️ the new regulatory moves by ANVISA (Brazilian Health Regulatory Agency) ⚠️ the risks of trivializing these medications ⚠️ and what separates pharmacies that are building authority… from those that just follow trends. Furthermore, I discuss Technical Note No. 7/2025 regarding the dispensing and handling of GLP-1 agonists and explain: ✔️ the increase in sanitary inspections ✔️ the risks related to the traceability and origin of raw materials ✔️ and how pharmacists should position themselves in this new scenario. 💬 Because the problem isn't just selling more. The problem is growing without compromising the credibility of your pharmacy. 🎯 If you are a pharmacist or owner of a compounding pharmacy, this episode is a must-see. 👇 COMMENT: What is your view on the current scenario of semaglutide and tirzepatide in the compounding market? 📌 SUBSCRIBE to the channel and activate notifications for more content about: • Compounding Pharmacy • Management and positioning • Regulatory and oversight • Pharmaceutical innovation • Strategic growth 🎓 Learn about the Postgraduate Program in Compounding Pharmacy: https://wa.me/message/4URQ4QDVZCLLB1 #Semaglutide #Tirzepatide #CompoundingPharmacy #CompoundingPharmacy #GLP1 #ABcast #Pharmacist #ANVISA #WeightLoss #Positioning #Pharmacy #PharmaceuticalManagement